Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Subscribe To Our Newsletter & Stay Updated
